INTRODUCTION {#SEC1}
============

Alternative splicing and adenosine (A) to inosine (I) RNA-editing are the two major co-transcriptional processes that greatly expand the diversity of mammalian transcriptomes. Both processes are coordinated with transcription and occur in the nucleus ([@B1]--[@B3]). Virtually every mammalian protein-coding transcript is subject to RNA-editing and about 95% of multiexon genes undergo alternative splicing ([@B4],[@B5]). Hence, both processes show a large overlap in the transcriptome. In particular, both mechanisms expand receptor diversity in the central nervous system (CNS) ([@B6],[@B7]). Alternative splicing as well as A to I editing have been implicated in a series of neurological disorders. This includes depression or amyotrophic lateral sclerosis in case of A to I editing defects or spinal muscular atrophy, Duchenne muscular dystrophy, schizophrenia and the Rett syndrome for splicing deficiencies ([@B8]--[@B11]). Together, this demonstrates the importance of a tight control of alternative splicing and RNA editing.

A to I editing is the most abundant form of RNA-editing in mammals. The reaction is mediated by adenosine deaminases acting on RNA (ADARs). In mammals two catalytically active ADAR enzymes, ADAR1 and ADAR2 (also known as ADARB1) and one inactive enzyme, ADAR3 have been identified in the soma ([@B12]). ADARs bind double-stranded and structured RNAs and convert adenosines to inosines by hydrolytic deamination. Inosines are interpreted as guanosines by most cellular machines. Thus, different processes can be affected, ranging from recoding of codons in mRNAs, over the masking of endogenous RNAs to the innate immune system, to changes in mRNA splicing ([@B12]--[@B16]).The consequences of A to I editing on mRNA splicing have been well documented for the transcript encoding glutamate receptor subunit 2 (*Gria2*). Editing of a single adenosine in exon 11 of the *Gria2* transcript, encoding the so-called Q/R site, is essential for mammalian life ([@B17]). The editing competent RNA-stem is formed by basepairing between exon 11 and intron 11 ([@B18]). Therefore, the pre-mRNA needs to be edited before removal of intron 11. Interestingly, lack of editing prevents splicing of intron 11 but not of other introns ([@B17]). Most likely, splicing is regulated by editing of two intronic hotspots ([@B19],[@B20]). Thus, editing at the intronic sites may act as a 'safe-guard' to ensure that only edited transcripts are spliced, exported and translated.

Most editing sites in the human transcriptome are found in Alu repeats that are typically located in non-coding parts of genes, like introns or UTRs ([@B4],[@B21]). However, a small fraction of editing sites is located in exons and can lead to non-synonymous codon changes or alter splice-sites ([@B12]). Interestingly, editing levels are highly variable between different substrate sites, different tissues and under different physiological and developmental conditions ([@B20]--[@B24]). These different editing levels can not solely be explained by varying ADAR protein levels as these have been shown to be relatively constant ([@B24]). Instead, additional factors such as regulatory- and competing proteins, RNA helicases or the local RNA-environment may contribute to the regulation of editing levels ([@B25]--[@B28]).

An important factor controlling the extent of editing may be the rate and efficiency of splicing. Editing sites are defined via base pairing with editing complementary sites (ECSs). For many exonic editing sites that lead to protein recoding, the ECS is located in an adjacent intron ([@B29]--[@B31]). Therefore, at these sites editing can only occur prior to intron removal. However, a fraction of protein-recoding editing sites rely on an ECS that is located within the same exon as the editing site ([@B29],[@B32]). Also in these latter cases, editing might be affected by pre-mRNA splicing as splicing efficiency is one of the most important factors determining nuclear retention time. In sum, it seems reasonable to assume that splicing efficiency may have a strong impact on A to I editing levels of sites residing in protein-coding exons.

To test this hypothesis we chose a set of exonic editing sites that depend on ECSs that are either located within an adjacent intron or within the same exon. To do so, the editing sites located in the transcripts encoding cytoplasmic FMR1-interacting protein 2 (*Cyfip2*) and the R/G editing site in glutamate receptor subunit 2 (*Gria2*) were chosen as examples for substrates with an intron-located ECSs ([@B29],[@B31]). Editing sites in the transcripts of the insulin-like growth factor-binding protein 7 (*Igfbp7*) and the gamma-aminobutyric acid receptor subunit alpha-3 (*Gabra3*) on the other hand, served as references for substrates with ECSs located in the same exon as the editing site ([@B29],[@B32]). The impact of splicing efficiency on editing levels was tested in a minigene approach by fusing the exons harboring the editing site including the downstream exonic or intronic ECS to heterologous intron/exon sequences with progressively weaker branch points. To back up data generated by this mutational approach we also used a splicing inhibitor to test the effect of splicing rates on editing of various substrates in primary cells.

MATERIALS AND METHODS {#SEC2}
=====================

Cloning of minigene constructs {#SEC2-1}
------------------------------

All minigene constructs are fusion constructs of an exonic sequence harboring one or two editing sites and an ECS fused to the last 61 basepairs of intron 2 plus exon 2 of the adenovirus major late transcript (AdML) ([@B33]). In the +/− and −/− versions the polypyrimidine tract sequence was mutated to weaken splicing efficiency. All sequences were introduced into pcDNA3.1(−) using *EcoRI* and *BamHI* for the test exon--intron part and *BamHI* plus *KpnI* for the AdML intron--exon part. The following exon--intron parts were cloned: *Gabra3-IS*: Exon 9 plus 161 basepairs of intronic sequence. *Gabra3*: Exon 9 plus 90 basepairs of intronic sequence. *Gria2*: Exon 13 plus 224 basepairs of intronic sequence. *Igfbp7*: Exon 1 plus 150 basepairs on intronic sequence. The polypyrimidine tract sequences have been as follows (the sequence including the terminal AG of the 3′ splice site is given; mutations are underlined):

  ----------------------------------------------------- -------------------------------------------------------
  (+/+) wild type:                                      5′-`TCCTGTCCCTTTTTTTTCCAC`**AG**-3′
  (+/−) for *Gabra3, Gabra3-IS, Cyfip2* and *Igfbp7*:   5′-`TCCTGTCCCTT`[GGGG]{.ul}`TTCCAC`**AG**-3′
  (−/−) for *Gabra3, Gabra3-IS, Cyfip2* and *Igfbp7*:   5′-`TCCTGTCCCTT`[GGGGAA]{.ul}`CCAC`**AG**-3′
  (+/−) for *Gria2*:                                    5′-`TCCTGTCCCTT`[G]{.ul}`TT`[G]{.ul}`TTCCAC`**AG**-3′
  (−/−) for *Gria2*:                                    5′-`TCCTGTCCCTT`[GGGG]{.ul}`TTCCAC`**AG**-3′
  ----------------------------------------------------- -------------------------------------------------------

In case of *Cyfip2*, nucleotide +128 (relative to the 5′ splice site) was changed from a G to an A using a mutational PCR in order to remove a cryptic splice site.

Transfection, RNA isolation, RT-PCR and Sanger sequencing {#SEC2-2}
---------------------------------------------------------

Twenty-four hours prior to transfection HEK293 cells were seeded in 35 mm dishes (2 × 10^5^ cells). The respective minigene plasmid was co-transfected with Flag-rADAR2 using jetPEI (Polyplus, France) following the manufacturer\'s instructions. To generate biological replicates, at least three independent transfections were made. For all constructs (except *Gabra3* constructs) 2 μg of minigene plasmid plus 2 μg Flag-rADAR2 were transfected. For *Gabra3* constructs we observed very high expression levels as compared to other constructs when we transfected 2 μg of plasmid and only moderate editing levels as compared to an earlier report ([@B34]). Thus, we reduced the amount of transfected minigene plasmid to 0.5 μg for *Gabra3*, to compensate for the elevated expression, and raised the amount of transfected Flag-rADAR2 to 3.5 μg. Forty-eight hours after transfection, RNA was isolated using TriFast (Peqlab, Germany) according to the manufacturer\'s guidelines. To remove traces of genomic DNA and plasmid DNA, 8 μg of isolated RNA were incubated with 3 μl of FastDigest BamHI (Thermo Scientific) at 37°C for 45 min (targeting the minigene constructs) followed by a digestion with 27 units of DNase I (Thermo Scientific) for 45 minutes at 37°C. Subsequently, RNA was phenol extracted. 1.7 μg of total RNA were reverse transcribed using random hexamer priming and RevertAid H Minus reverse transcriptase (Thermo Scientific) following manufacturer\'s instructions. A control without reverse transcriptase was included for every sample. To amplify products for Sanger sequencing, Taq-polymerase (Thermo Scientific) was used (except for *Igfbp7* constructs) with the following standard PCR protocol: 3 min at 95°C followed by 33 cycles 95°C (30 s), 58°C (30 s), 72°C (30 s). For *Igfbp7* constructs Phusion polymerase (Thermo Scientific) and GC buffer was used: 30 s 98°C, followed by 30 cycles of 98°C (10 s), 60°C (30 s), 72°C (20 s) and a final elongation of 3 min at 72°C. A semi-nested PCR was done for *Igfbp7* pre-mRNA and mRNA, *Gabra3* pre-mRNA, *Cyfip2* pre-mRNA and mRNA and *Gria2* pre-mRNA. The PCR products representing pre-mRNAs and mRNAs were gel purified. Sanger sequencing was done using the eluted PCR products and the reverse primer of the first or the semi-nested PCR. Only in case of *Gabra3, Gabra3-IS, CyFip2 and Gria2* PCR products the respective forward primer was used for sequencing. The percentage of editing is defined as the height of the G peak divided by the sum of the A + G peaks (In case of the reverse primer: the height of the T peak divided by the sum of the T + C peaks). In order to estimate splicing efficiency of the minigene constructs PCR cycle numbers were reduced (*Gabra3* constructs: 25 or 22 cycles; *Igfbp7* and *Cyfip2* constructs: 30 cycles; *Gria2* constructs: 25 cycles). If not stated otherwise, a unique forward primer specific for the respective construct was combined with the universal reverse primer binding in AdML exon 2. Primer sequences are as follows: Universal AdML exon 2 primer: Rev 5′-GAAAGACCGCGAAGAGTTTG-3′, *Gabra3* constructs: Fwd 5′-TGCTTACCATGACCACCTTG-3′, pre-mRNA-nested Rev 5′-CTATAGGCTGCCCACTCCTG-3′, *Cyfip2* constructs: Fwd 5′-GCCACTGTGCTGGATATCTG-3′, pre-mRNA-nested Rev 5′-CGGGAGCCGAGAGACATTAC-3′, mRNA-nested Fwd 5′-CAGCTGCAGGTGGTGC-3′, *Gria2* constructs: Fwd 5′-CAAAGGAAGCCTTGCGACAC-3′, pre-mRNA-nested Rev 5′-CATCAGGGTAGGTGGGATACT-3′, *Igfbp7*-constructs: mRNA Fwd 5′-TCTTCCTCCTCTTCGGACAC-3′, mRNA-nested Rev 5′-GGGTAGCGGCTCTTGCAC-3′, pre-mRNA Fwd 5′-GGCTGCTGCCCTATGTGC-3′, pre-mRNA Rev 5′-CCAACTCTTTCCCTCCCATC-3′, pre-mRNA-nested Rev 5′-AGGGTTGGAGAGGGAAGC-3′.

Actinomycin D treatment and nuclear versus cytoplasmic separation {#SEC2-3}
-----------------------------------------------------------------

For actinomycin D (AMD) (Sigma Aldrich, MO) treatment, HEK293 cells were co-transfected as described above and treatment with AMD was done 48 h after transfection for 0, 2 and 6 h at a concentration of 5 μg/ml. For nuclear versus cytoplasmic separation, cells were seeded into 10 cm dishes (1 × 10^6^ cells) 24 h prior to transfection. Transfection was done as described above, but using 4 μg of Flag-rADAR2 and 4 μg of the least efficiently spliced version of the *Igfbp7* minigenes. Forty-eight hours after transfection nuclear versus cytoplasmic separation was done as described previously ([@B35]). Antibodies against histone H3 or GAPDH were used to probe for the nuclear and cytoplasmic fractions, respectively. RNA isolation, RT and PCR was done as described above.

Isolation and culturing of primary cells and splicing inhibition {#SEC2-4}
----------------------------------------------------------------

Bone marrow was isolated as described previously ([@B36]). Briefly, bone marrow was isolated from the femurs and tibiae of 8--10 week old mice. Cultures were established in RPMI medium (supplemented with 10% FBS, penicillin streptomycin, gentamycin and L-glutamine). Sixteen hours after establishing the cultures, splicing inhibition was performed using meayamycin at a concentration of 5 nM for 6 h. DMSO was used as a vehicle control. Meayamycin is a potent inhibitor of splicing which interferes with the U2 snRNP associated protein SF3b and is active already at low nanomolar concentrations ([@B37]). Primary neuronal cultures were established from mouse embryos at embryonic day 11.5. Each embryo isolate was split into two wells of a 6-well dish coated with poly-D-lysine. Neuronal cells were subsequently cultured in neurobasal A medium (supplemented with B27, penicillin, streptomycin, gentamycin and L-glutamine) for 2 weeks. To prevent outgrowth of dividing cells, Cytosine β-D-arabinofuranoside (Ara-C) (Sigma Aldrich, MO) was added to 1 μM after 48 h. After 96 h the concentration was raised to 5 μM. For splicing inhibition, cells were treated with meayamycin at a concentration of 15 nM or DMSO as control. RNA was isolated using TriFast (PeqLab) and DNaseI treated (Thermo Fisher Scientific) following the manufacturer\'s instructions. RT and PCR was done as described above. The following primer sequences were used: *Cog3* Fwd 5′-TCAGATTGATGGACAACTTTTCTT-3′, *Cog3* Rev 5′-AAGGCATTGTTGCTATTCAGC-3′, *Cyfip2* Fwd 5′-TGCAGGTGGTACCCCTTT-3′, *Cyfip2* Rev 5′-ATCCCGGATCTGAACCATCTG-3′, *Exoc8* Fwd 5′-CAAGGGTTTCTCTGTATAGC-3′, *Exoc8* Rev 5′-GGTTTCAGCACCCACATTCT-3′, *Gabra3* Fwd 5′-TCTCACCATGACCACCTTGA-3′, *Gabra3* Rev 5′-GTTGGAGCTGCTGGTGTTTT-3′, *Gria2* Fwd 5′-GTGAGGACTACGGCAGAAGG-3′, *Gria2* Rev 5′-GTCCAACAGGCCTTGTTCAT-3′, *Igfbp7* Fwd 5′-CCCCTCTCCTCTTCCTCCTC-3′, *Igfbp7* Rev 5′-GGTAGCGGCTCTTGCACA-3′, *Pum2* Fwd 5′-AAACTGGCTTGCAGTCTGGT-3′, *Pum2* Rev 5′-TGTCAGGGACATTATAGGGCAG-3′, *Sfi1* Fwd 5′-CGTCTCCAGAACTGGTTTCAG-3′, *Sfi1* Rev 5′-GAGTCTCTGTGCCAGGAGTTG-3′, *Vcp* Fwd 5′-CGATGAGCTTGATGCCATT-3′, *Vcp* Rev 5′-CTCTGCTTTAGGCCATCCAT-3′.

RESULTS {#SEC3}
=======

Editing sites guided by intronic ECSs are affected by splicing rates {#SEC3-1}
--------------------------------------------------------------------

To test whether splicing efficiency controls the rate of A to I editing we chose a set of model substrates. The transcript of *Cyfip2* contains one editing site (K/E-site) in exon 9 at position -35 relative to the next downstream 5′ splice site (5′ ss). The ECS is situated in the adjacent intron, approximately 10 to 20 nucleotides downstream of the 5′ ss. To manipulate splicing efficiency, we used a minigene approach. The *Cyfip2* exon 9 including parts of the downstream intron (spanning the ECS) was fused to three variants of a heterologous intron--exon sequence that differed exclusively in their polypyrimidine tracts giving rise to gradually reduced splice efficiency (Figure [1A](#F1){ref-type="fig"}). The minigene constructs were co-transfected with a plasmid expressing rat ADAR2 into HEK293 cells. As expected and confirmed by RT-PCR the polypyrimidine tract mutations led to reduced splicing efficiency (Figure [1B](#F1){ref-type="fig"}). When editing levels of corresponding pre-mRNAs and mRNAs were determined by Sanger sequencing, strong changes were observed (Figure [1C](#F1){ref-type="fig"}). With decreasing splicing efficiency, editing increased from 26 to 37% in the mRNA and from 52 to 66% in the pre-mRNA. Interestingly, editing levels are generally higher in pre-mRNAs compared to the corresponding mRNAs. Also, editing levels in the pre-mRNA increase continuously with a reduction in splicing while the corresponding mRNA-editing levels reach a plateau at intermediate splicing levels (Figure [1C](#F1){ref-type="fig"}). The generally higher editing levels in nuclear pre-mRNAs together with a plateau in mRNA editing suggests that mRNA-maturation steps such as splicing and export may control the level of edited cytoplasmic mRNA.

![Reduced splicing efficiency enhances exonic editing at sites depending on intronic ECSs (**A**) Model for the K/E editing site in *Cyfip2* exon 9 that is defined between an exon and intron (exon in blue, downstream exon in red, intron is depicted as a thin line; +/+, +/−, −/− indicates a strong, intermediate or weak polypyrimidine tract). (**B**) RT-PCR with exon-specific primers to estimate splicing efficiency of *Cyfip2* transcripts with a strong, intermediate or weak polypyrimidine tract (+/+, +/−, −/−). Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. (**C**) Sanger sequencing of the RT-PCR-products derived from *Cyfip2* pre-mRNA or mRNA. Shown is a representative sequencing chromatogram. The average plus standard deviation of three biological replicates is depicted next to the chromatograms as a bar chart (orange = pre-mRNA, green = mRNA) and in numbers below the chromatograms. The edited adenosine is marked by a vertical line underneath the chromatogram. Panels (**D**--**F**): Model, splicing efficiency and sequencing chromatograms for the *Gria2* R/G-site. For the editing targets *Cyfip2* and *Gria2*, editing frequency increases when splicing efficiency is impaired. Both editing sites are coordinated with an ECS in the downstream intron. Interestingly, pre-mRNA editing is higher than mRNA editing for both targets.](gkw325fig1){#F1}

The *Gria2* R/G site was used as another model substrate where editing is guided by intronic elements. The R/G site is located in exon 13 at position -2 relative to the 5′ ss. Again three fusion minigenes were constructed, each encompassing exon 13 of the *Gria2* transcript including a part of the adjacent downstream intron 13 (including the ECS) followed by heterologous downstream intron--exon sequences with altered branch points (Figure [1D](#F1){ref-type="fig"}). As for the *Cyfip2* minigenes, reduced splicing efficiencies were observed with weaker polypyrimidine tracts (Figure [1E](#F1){ref-type="fig"}). Subsequently, editing levels were determined by direct sequencing of PCR products obtained for pre-mRNAs and spliced mRNAs. Strikingly, the editing frequencies at the R/G site (position - 2) gradually increased from 13 over 45% and even 59% with reduced splicing efficiency (Figure [1F](#F1){ref-type="fig"}). Editing was also detected at position -3 where editing levels similarly increased when splicing efficiency was reduced. Editing in the *Gria2* pre-mRNA was not precisely quantifiable at position -2 as the G-peak was fused with the neighboring G-peak in most chromatograms (Figure [1F](#F1){ref-type="fig"}). Still, while not exactly quantifiable, it was obvious that editing levels also increased in the *Gria2* pre-mRNA with reduced splicing efficiency. Pre-mRNA-editing at position -3 dramatically increased upon reduced splicing efficiency from about 10% for the most efficiently spliced reporter construct (+/+) to almost 70% for the most inefficiently spliced reporter (−/−). Again, as seen for the *Cyfip2* minigenes higher editing levels were observed in pre-mRNAs compared to mRNAs. Thus, for both substrates in which editing depends on intronic elements a strong correlation between reduced splicing efficiency and increased editing levels can be observed.

Next, we tested whether splicing can also control editing if the double-stranded RNA (dsRNA) structure required for editing is formed within the exon itself. In this case, splicing efficiency might indirectly control editing by influencing nuclear retention times. To address this question, we chose *Igfbp7* as a model substrate. The *Igfbp7* transcript contains two editing sites, a Q/R site and a K/R site. Both sites are located in exon 1 and are distant to a splice site (Figure [2A](#F2){ref-type="fig"}). Again the sequence for exon 1 and a part of the downstream intron 1 was fused to intron--exon sequences with progressively weaker 3′ splice sites. The impact on splicing was confirmed using RT-PCR (Figure [2B](#F2){ref-type="fig"}). In contrast to constructs where the editing sites were defined by basepairing of exonic and intronic sequences, editing levels were unaffected by splicing efficiency in mRNAs with strictly exon-dependent editing sites. Here, editing levels stayed at about 33 and 74% for the Q/R and K/R site, respectively (Figure [2C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). Interestingly, editing levels were again higher in pre-mRNAs than in the mature mRNAs. For the Q/R site a moderate increase in editing from 80 to 86% was observed in the pre-mRNA upon reduction of splicing efficiency while only negligible changes were observed at the K/R site (93 to 95%). We also detected promiscuous editing at several sites in the *Igfbp7* pre-mRNA that increased with reduced splicing efficiency. One of these sites we quantified and observed an increase in editing from 36 to 52% (compare chromatograms +/+ and −/− in Figure [2E](#F2){ref-type="fig"}). Most interestingly, no detectable promiscuous editing could be seen in the mature mRNA (Figure [2E](#F2){ref-type="fig"}), again indicating selective splicing, export or turnover of edited and unedited transcripts. Taken together, the findings seen for the *Igfbp7* editing sites suggest that splicing does not control the percentage of editing for the strictly exonically defined Q/R and K/R editing sites but may have an effect on the specificity of editing sites.

![Editing in *Igfbp7* mRNA containing an exonic ECS is not affected by splicing while pre-mRNA editing is increased. (**A**) Model of the editing sites in *Igfbp7* exon1. Two canonical editing sites (Q/R and K/R) and a promiscuous editing site (prom. site) are given (the exon is depicted in blue, downstream exon in red, intron is depicted as a thin line; +/+, +/−, −/− indicates a strong, intermediate or weak polypyrimidine tract). (**B**) RT-PCR with exon-specific primers to estimate splicing efficiency of *Igfbp7* transcripts with a strong, intermediate or weak polypyrimidine tract (+/+, +/−, −/−). Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. (**C**--**E**) Sanger sequencing of the RT-PCR-products representing *Igfbp7* pre-mRNA or mRNA. Shown is a representative sequencing chromatogram and the average plus standard deviation of three biological replicates is given below in numbers and next to the chromatograms as bar charts (orange = pre-mRNA, green = mRNA). The edited adenosine is marked by a vertical line underneath the chromatogram. (C and D) The editing frequencies for pre-mRNA and mRNAs in *Ifgbp7* do not change when splicing efficiency decreases. Note that the editing-competent duplex is formed within the exon itself. Interestingly, the editing levels for pre-mRNAs are higher than for mRNAs. E) A promiscuous editing site was detected in *Igfbp7* pre-mRNA, which could not be seen in mRNA at all. Thus, this represents an extreme case where edited adenosines in pre-mRNA are completely unedited in the respective mRNA.](gkw325fig2){#F2}

Finally, we choose the *Gabra3* transcript as an additional model substrate for a strictly exonically defined editing site. *Gabra3* contains the so-called I/M editing site in exon 9. It was also shown that an intronic stem structure in intron 9 can enhance editing at the I/M site ([@B34]). Thus, we reasoned that this enhancing effect might also be affected by splicing rates. To test this, two sets of *Gabra3* reporter constructs were generated; one encompassing the entire intronic stem structure (*Gabra3-IS*) and one with the stem structure deleted (*Gabra3*; Figure [3A](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). Again, editing levels of the pre-mRNA were increasing upon reduced splicing efficiency for both, the *Gabra3--IS* and the *Gabra3* reporter constructs (Figure [3B](#F3){ref-type="fig"} and [E](#F3){ref-type="fig"}). However, editing levels in the mature mRNA remained constant (Figure [3C](#F3){ref-type="fig"} and [F](#F3){ref-type="fig"}). Again a particular editing state might be preferentially spliced, exported or stabilized and thus compensate for the differences seen between pre-mRNA and mRNA. The *Gabra3--IS* and *Gabra3* reporter constructs differ only slightly in the extent of editing. Editing levels were only moderately higher for the *Gabra3--IS* constructs than the *Gabra3* constructs, both, at the pre-mRNA and mRNA levels. Thus, at least in the context of our transiently transfected reporter constructs the intronically located stem structure has little effect on editing levels ([@B34]).

![I/M site editing in *Gabra3* transcripts with or without an intronic stem. (**A**) The I/M editing site is defined by an ECS in exon 9. (The exon is depicted in blue, downstream exon in red, intron is depicted as a thin line; +/+, +/−, −/− indicates a strong, intermediate or weak polypyrimidine tract). Intron 9 contains a long intronic stem (intronic stem, IS). (**B**) RT-PCR using exon-specific primers shows a reduction of splice efficiency for *Gabra3*-IS transcripts with a strong, intermediate or weak polypyrimidine tract (+/+, +/−, −/−). Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. The PCR has been done also with 22 cycles (lower panel) (**C**) Sanger sequencing of the RT-PCR-products representing *Gabra3*-IS pre-mRNA or mRNA. Shown is a representative sequencing chromatogram and the average plus standard deviation of three biological replicates is given below and as a bar chart next to the chromatograms (orange = pre-mRNA, green = mRNA). The edited adenosine is marked by a vertical line underneath the chromatogram. While no differences in editing levels can be seen in the mature mRNAs, a reduction of splicing efficiency leads to a clear increase in editing in the pre-mRNA. (**D**) A model of the *Gabra3* editing site in exon 9 but lacking the intronic stem. (**E** and **F**) Compare with panels (B and C) for description. The lack of the intronic stem only modestly affects editing levels and exhibits the same response to reduced splicing efficiency as observed for *Gabra3*-IS.](gkw325fig3){#F3}

Editing and ADAR2-binding of splice-proximal regions affect splicing rates {#SEC3-2}
--------------------------------------------------------------------------

Our data have shown a surprising difference between editing levels in pre-mRNA and mRNA. This discrepancy could be the result of differential nuclear export, stability or selective processing of edited versus unedited transcripts.

We therefore separated nuclei from cytoplasm of transfected cells and determined editing levels in spliced transcripts of the least efficiently spliced *Igfbp7* reporter in both fractions (Supplementary Figure S1). This *Igfbp7* reporter had shown the strongest difference in editing levels of pre-mRNA and mRNA. However, no difference in editing levels was observed between spliced nuclear and cytoplasmic transcripts, indicating that selective nuclear export is probably not responsible for the different editing levels observed in pre-mRNAs and mRNAs. Next, we tested whether the stability of mRNAs would be affected by their editing levels. We therefore inhibited transcription of cells transfected with reporter constructs using actinomycin D (AMD). Subsequently cells were harvested and RNAs extracted after 0, 2 and 6 h of AMD treatment. Editing levels were determined in those RNAs. However, no differences in editing levels were observed over time, indicating that edited and unedited mRNAs had the same stability (data not shown).

We therefore tested whether edited and unedited pre-mRNAs might be selectively spliced. To do so we mutated the *Gria2* minigenes that contain a canonical editing site at position -2 and a facultative editing site at -3, relative to the 5′ splice site. To mimic editing, the A at position -2 was replaced by a 'pre-edited' G. Similarly, we made constructs with guanosines at positions -2 and -3. The constructs termed 'pre-edited -2' and 'pre-edited -2-3′ were again co-transfected with ADAR2, with the 'wildtype' constructs serving as controls. The ratios of pre-mRNA to mRNA were determined by PCR using a reduced number of cycles. A significant increase of pre-mRNA was observed for the pre-edited -2 versions for one of the *Gria2* minigenes (+/−; Supplementary Figure S2). An even stronger accumulation of pre-mRNA was observed for the pre-edited -2-3 constructs in context with the strongest and weakest branch points (Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}). This demonstrates that guanosines and therefore most likely also inosines introduced by editing can interfere with splicing of the *Gria2* minigene.

![Editing and ADAR2-binding reduces splicing efficiency at the *Gria2* R/G site. (**A**) RT-PCR shows a gradual reduction of splicing in the presence of a strong (+/+), intermediate (+/−) or weak (−/−) polypyrimidine tract in wildtype (wt) or pre-edited (pre-ed) versions of a Gria2 exon 13 minigene. Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. A white asterisk marks an aberrant splicing product. (**B**) The relative splicing efficiency---measured from the gel in panel A---is given as % unspliced product. Pre-editing reduces splicing efficiency. Quantification was done from three independent biological replicates. (\* *P*-value \< 0.05; n.s. not significant). Dark gray = wt, light gray = pre-edited at position -2-3. (**C**) RT-PCR of *Gria2* reporter transcripts in the presence (y) or absence (n) of ADAR2 indicate a strong reduction in splicing in the presence of ADAR2. Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. (**D**) The splicing efficiency---deduced from the gel in panel (C)---in percent unspliced transcript is given. The presence of ADAR2 reduces splicing efficiency. The quantification was done from three independent biological replicates (n.s. not significant, \* *P*-value \< 0.05; \*\* *P*-value \< 0.01).](gkw325fig4){#F4}

Surprisingly, when we transfected the *Gria2* minigene (+/+) without the addition of the ADAR2 plasmid we observed a strong reduction in pre-mRNA (Figure [4C](#F4){ref-type="fig"} and [D](#F4){ref-type="fig"}). Conversely, an increase in pre-mRNA accumulation was observed when the pre-edited -2 version of *Gria2* was co-transfected with ADAR2. It thus appears that ADAR2 binding alone impairs splicing, even when editing cannot take place. Possibly, binding of ADAR2 interferes with spliceosome assembly at the stage of U1 snRNP binding. Taken together, our data show that editing at positions -2 and -3 as well as ADAR2 binding reduce splicing efficiency of *Gria2* with ADAR2 binding having the more pronounced effect. Jointly, both effects can explain the observed differences in pre-mRNA and mRNA editing levels since unedited pre-mRNAs not bound by ADAR2 will be preferentially spliced.

Inhibition of splicing increases editing in endogenous exon--intron substrates {#SEC3-3}
------------------------------------------------------------------------------

The minigene-based experiments have demonstrated that editing levels increase with a decrease in splicing efficiency when editing sites are defined by intron--exon basepairing. Strictly exon-dependent editing sites are much less affected. To test if these findings can be reproduced in a chromosomal environment, we employed the splicing inhibitor meayamycin that interferes with early spliceosomal assembly ([@B37]). For this we needed to identify cells that express and edit endogenous substrates at constant and reproducible levels. Screening of several tissues identified bone marrow cells isolated from 8 to 10 weeks old mice and primary neurons isolated from mouse embryos at embryonic day 11.5 as a suitable system. Meayamycin at a concentration of 5 nM was sufficient to efficiently inhibit splicing in bone marrow (Figure [5A](#F5){ref-type="fig"}). A target where editing is guided by an intronic element is *Cog3* containing an I/V recoding editing site in exon 17 at position -28 relative to the 5′ ss ([@B38]) (Figure [5B](#F5){ref-type="fig"}). Meayamycin treatment led to a 3-fold increase in editing (Figure [5C](#F5){ref-type="fig"}). *Sfi1* contains several editing sites ([@B39]). A synonymous editing site is located in exon 22, which is again guided by intronic elements. Editing levels increased 4-fold upon meayamycin treatment (Figure [5D](#F5){ref-type="fig"}). Next, we tested editing in endogenous *Igfbp7* where the editing sites contain an ECS in the same exon (Figure [5E](#F5){ref-type="fig"}). As in the reporter assays editing efficiencies did not respond to splicing inhibition neither for the Q/R nor the K/R site (Figure [5F](#F5){ref-type="fig"} and [G](#F5){ref-type="fig"}). In order to expand the panel of tested substrates even more, we picked two additional substrates where the tested editing site is located in the 3′ UTR (Figure [5H](#F5){ref-type="fig"}). First, we monitored editing in the *Pum2* transcript. Editing levels remained unchanged upon meayamycin treatment (Figure [5I](#F5){ref-type="fig"}). For the transcript coding for the protein Exocyst Complex Component 8 (EXOC8) we observed a small increase in editing of one out of two tested sites. The *Exoc8* transcript contains only one exon and should not be directly affected by splicing inhibition. As expected, editing does not change for editing site 1 (Figure [5J](#F5){ref-type="fig"}). Surprisingly, however, a modest increase in editing was observed at site 2 (Figure [5K](#F5){ref-type="fig"}), which we cannot explain at present. Still, taken together these experiments show that inhibition of splicing strongly affects editing of endogenous substrates when the exonic editing event is guided by intronic elements (Figure [5L](#F5){ref-type="fig"}). As expected, editing sites that do not depend on intronic structures are almost unaffected by inhibition of splicing (Figure [5M](#F5){ref-type="fig"}).

![Splicing inhibition increases editing rates at intron-dependent sites *in vivo*. (**A**) RT-PCR shows a reduction of splicing efficiency of *Sfi1* exon 22 upon addition of meayamycin. Total RNA was prepared from bone marrow cells MOCK-treated (DMSO) or treated with the splicing inhibitor meayamycin (MEA). Pre-mRNA and mRNA are indicated at the right side of the panel. M = size standard. bp = basepairs. (**B**) Scheme of an exonic editing site defined by an ECS in the intron. +/− MEA indicates splicing inhibition or control. (**C** and **D**) Sanger sequencing of the *Cog3* or *Sfi1* mRNAs RT-PCR-products shows a strong increase in editing upon addition of the splicing inhibitor meayamycin (MEA). (**E**) Scheme of a generic exonic editing site defined by an ECS in the exon. (**F** and **G**) Sanger sequencing of the mRNA of the *Igfbp7* Q/R or K/R editing site shows no change in editing patterns upon splicing inhibition. The average and standard error of the mean of three biological replicates is given below each chromatogram. (**H**) Scheme of a generic 3′ UTR editing site defined by an ECS in the exon. (**I, J** and**K**) Sanger sequencing of the mRNA of an editing site in the 3′ UTR of *Pum2* or two sites in the 3′ UTR of *Exoc8* shows significant effects on editing upon inhibition of splicing only for *Exoc8*-site2. (**L**) Graphs of editing frequencies of all intronically guided transcripts or (**M**) exonically defined editing sites in Figure [5](#F5){ref-type="fig"}. The significance level is given on top (n.s. not significant, \* *P* \< 0.05, \*\* *P* \< 0.01). Blue = DMSO, red = meayamycin.](gkw325fig5){#F5}

Finally, we used primary neurons to follow editing of the endogenously expressed transcripts *Cyfip2, Gria2, Gabra3 and Igfbp7* (Figure [6](#F6){ref-type="fig"}). Primary neuronal cultures were established from embryos at embryonic day 11.5. In contrast to bone marrow meayamycin was used at a concentration of 15 nM to affect splicing (Figure [6A](#F6){ref-type="fig"}). We observed similar trends as we have seen for the minigene constructs and for the bone marrow setting. Editing for intronically guided editing sites increases (Figure [6B](#F6){ref-type="fig"}--[D](#F6){ref-type="fig"} and [I](#F6){ref-type="fig"}), whereas editing for *Gabra3 and Igfbp7*---both containing editing sites coordinated within the exon---remain the same (Figure [6](#F6){ref-type="fig"} E--H and J).

![Splicing inhibition in primary neurons leads to an increase in editing rates of intron-dependent editing. (**A**) RT-PCR to estimate splicing efficiency upon treatment with meayamycin using the short intron 8 in the *Vcp* transcript coding for the valosin containing protein. As editing targets shown in the figure contain large introns, the *Vcp* transcript was used as an independent control to validate splicing inhibition. Primers bind to exons 8 and 9. M = size standard. bp = basepairs. (**B**) Scheme of a generic exonic editing site defined by an ECS in the intron. +/− MEA indicates splicing inhibition or control. Sanger sequencing shows an increase in editing rates for intron-dependent editing sites (**B, C** and **D**) but not for exon-dependent editing sites (**E, F, G** and **H**) upon meayamycin treatment (MEA). The average and standard error of the mean of six biological replicates is given below each chromatogram. (**I**) Graphs depicting editing frequencies of all intronically and exonically (**J**) defined editing sites in the figure. The significance level is given on top (n.s.: not significant, \*\* *P* \< 0.01, \*\*\* *P* \< 0.001). Blue = DMSO, red = meayamycin.](gkw325fig6){#F6}

DISCUSSION {#SEC4}
==========

In this study, we have addressed the impact of splicing efficiency on editing frequencies both in pre-mRNAs and in mRNAs. Using two different approaches we find that a reduction in splicing efficiency leads to a clear increase in editing levels when the editing competent stem is formed between an exon and an intron. Thus, splicing efficiency can have a dramatic impact on the level of editing. However, when the editing competent duplex is formed within the edited exon itself, editing levels do not change in the mature mRNA. Extrapolating from the eight substrates tested, this principle most likely will apply to most if not all exonic editing sites. Interestingly, we observe different *Igfbp7* editing levels for the Q/R and K/R site in bone marrow and primary neuronal cultures, respectively (compare Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). While editing of the Q/R and K/R site reaches 70 and 60%, respectively, in bone marrow cells, the levels are at 26 and 22% in the primary neuronal cultures. This is most likely resulting from developmental differences in editing levels which are known to increase with age. As the neuronal cultures were derived from early embryos while the bone marrow cells were derived from adult mice, differences in editing levels can be expected ([@B24],[@B40]).

A striking difference between editing levels in pre-mRNA and mRNA was observed, in particular for the *Gria2* substrate where editing is higher in the pre-mRNA than in the mRNA (Figure [1](#F1){ref-type="fig"}). Our experiments indicate that this can be explained by selective splicing and ADAR2-binding to the pre-mRNA. Apparently ADAR-binding but also the presence of guanosines (and most likely also inosines) at a position -2 relative to a 5′ splice site interferes with binding of the U1 snRNP. These findings are in agreement with earlier data that show selective splicing of *Gria2* exon 13 containing the R/G editing site ([@B19]). Feed-back of the editing state on pre-mRNA splicing was also reported in other contexts ([@B20],[@B41]). The finding that ADAR2 binding reduces splicing efficiency also fits very well with the assumption that editing needs to happen before splicing as exonic editing sites are frequently coordinated by an intronic ECS ([@B31]). This notion is also supported by analysis of nascent RNA by RNA-seq that shows that editing occurs co-transcriptionally before most of the introns are removed ([@B42]). ADAR2-binding may also explain the higher editing levels in the pre-mRNAs of other constructs. Moreover, ADAR-binding might generally interfere with spliceosomal assembly or the binding of accessory splicing factors, thereby assuring that editing can occur before the mRNA is matured and exported from the editing-competent nucleus.

Surprisingly, *Gabra3* mRNAs showed higher editing levels than the corresponding pre-mRNAs. This may indicate selective maturation of the edited transcript. Alternatively, as *Gabra3* editing does not require intronic sequences, editing may still continue after splicing as long as the mRNA has not left the editing-competent nucleus. For *Gabra3* we have also tested two minigene versions. One version contains an intronic stem while the other is lacking the intronic stem. Previous work has shown that the intronic stem in *Gabra3* increases editing at the nearby exonic site ([@B34]). Using our constructs we only observe a minor increase in editing upon addition of the intronic stem which is in contrast to the strong increase reported earlier ([@B34]). A likely explanation in the observed differences may lie in the different design of the constructs used. While we used an exon--intron--exon context, the most dramatic effect of the intronic stem was observed for an exon--intron construct only. Addition of a second exon did in fact also diminish the effect exerted by the intronic stem ([@B34]).
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